C1S fundamentals
An in-depth look to China Shineway Pharmaceutical Group Ltd. operating, investing, and financing activities
C1S free cash flow for H2 23 is 76.44 M EUR. For 2023, C1S free cash flow was 108.9 M EUR and operating cash flow was 127.4 M EUR.
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
TTM